Evidence map›Paper›PMID 32051231›Full record

ArticleMolecular cancer research : MCR2020

Nucleostemin Modulates Outcomes of Hepatocellular Carcinoma via a Tumor Adaptive Mechanism to Genomic Stress.

Junying Wang, Daniel J McGrail, Parnit K Bhupal, Wen Zhang, Kuan-Yu Lin, Yi-Hsuan Ku, Tao Lin, Hongfu Wu, Kyle C Tsai, Kaiyi Li and 4 more

Open access · hybridAbstract read
In one paragraph

Article in Molecular cancer research : MCR, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 3 countries.

Junying WangInstitute of Biosciences and Technology, Texas A&M University, Houston, Texas.
Daniel J McGrail *Department of Systems Biology, MD Anderson Cancer Center, Houston, Texas.
Parnit K Bhupal *Institute of Biosciences and Technology, Texas A&M University, Houston, Texas.
Wen ZhangInstitute of Biosciences and Technology, Texas A&M University, Houston, Texas.
Kuan-Yu LinInstitute of Biosciences and Technology, Texas A&M University, Houston, Texas.
Yi-Hsuan KuInstitute of Biosciences and Technology, Texas A&M University, Houston, Texas.ORCID 0000-0001-7542-6696
Tao LinInstitute of Biosciences and Technology, Texas A&M University, Houston, Texas.
Hongfu WuInstitute of Biosciences and Technology, Texas A&M University, Houston, Texas.
Kyle C TsaiMichael E. DeBakey High School for Health Professions, Houston, Texas.ORCID 0000-0002-8357-0812
Kaiyi LiDepartment of Surgery, Baylor College of Medicine, Houston, Texas.
Cheng-Yuan PengDivision of Hepatogastroenterology, Department of Internal Medicine, China Medical University Hospital, School of Medicine, China Medical University, Taichung, Taiwan.
Milton J FinegoldDepartment of Pathology & Immunology, Baylor College of Medicine, Houston, Texas.
Shiaw-Yih LinDepartment of Systems Biology, MD Anderson Cancer Center, Houston, Texas.
Robert Y L TsaiInstitute of Biosciences and Technology, Texas A&M University, Houston, Texas. robtsai@tamu.edu.ORCID 0000-0002-8357-0812
Texas A&M University · USBaylor College of Medicine · USThe University of Texas MD Anderson Cancer Center · USChina Medical University · TWFudan University · CNMichael E. DeBakey VA Medical Center · US

Funding

Tissue Analysis & Molecular Imaging CoreP30DK056338 · NIDDK · BAYLOR COLLEGE OF MEDICINE · PI James Versalovic · 2001 to 2026
$28.3M
Aging Effect on Genome Maintenance during Hepatocyte RegenerationR21AG052006 · NIA · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI TSAI, ROBERT Y · 2016 to 2017
$408k
Role of Nucleostemin in Conferring The Drug Resistance of Hepatocellular CarcinomaR03CA201988 · NCI · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI TSAI, ROBERT Y · 2016 to 2017
$149k
NCI NIH HHS R03 CA201988NIA NIH HHS R21 AG052006NIDDK NIH HHS P30 DK056338
6 · The paper itself

Abstract

Hepatocellular carcinomas (HCC) are adapted to survive extreme genomic stress conditions imposed by hyperactive DNA replication and genotoxic drug treatment. The underlying mechanisms remain unclear, but may involve intensified DNA damage response/repair programs. Here, we investigate a new role of nucleostemin (NS) in allowing HCC to survive its own malignancy, as NS was previously shown to promote liver regeneration via a damage repair mechanism. We first established that a higher NS transcript level correlates with high-HCC grades and poor prognostic signatures, and is an independent predictor of shorter overall and progression-free survival specifically for HCC and kidney cancer but not for others. Immunostaining confirmed that NS is most abundantly expressed in high-grade and metastatic HCCs. Genome-wide analyses revealed that NS is coenriched with MYC target and homologous recombination (HR) repair genes in human HCC samples and functionally intersects with those involved in replication stress response and HR repair in yeasts. In support, NS-high HCCs are more reliant on the replicative/oxidative stress response pathways, whereas NS-low HCCs depend more on the mTOR pathway. Perturbation studies showed NS function in protecting human HCC cells from replication- and drug-induced DNA damage. Notably, NS depletion in HCC cells increases the amounts of physical DNA damage and cytosolic double-stranded DNA, leading to a reactive increase of cytokines and PD-L1. This study shows that NS provides an essential mechanism for HCC to adapt to high genomic stress for oncogenic maintenance and propagation. NS deficiency sensitizes HCC cells to chemotherapy but also triggers tumor immune responses. IMPLICATIONS: HCC employs a novel, nucleostemin (NS)-mediated-mediated adaptive mechanism to survive high genomic stress conditions, a deficiency of which sensitizes HCC cells to chemotherapy but also triggers tumor immune responses.

Indexed as

DNA DamageDrug Resistance, NeoplasmGene Expression Regulation, NeoplasticGenomic InstabilityAntineoplastic AgentsBiomarkers, TumorCarcinoma, HepatocellularGenome, HumanGenome-Wide Association StudyGTP-Binding ProteinsHumansLiver NeoplasmsNuclear ProteinsPrognosisSurvival RateAntineoplastic AgentsBiomarkers, TumorGNL3 protein, humanGTP-Binding ProteinsNuclear Proteins

Identifiers

PMID32051231
PMCPMC7202947
OpenAlexW3005952574

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.